PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
53.82%
Cash & equivalents yoy growth at least 1.5x TRVN's 9.60%. Mohnish Pabrai might see this as a favorable liquidity edge, provided funds are well deployed.
No Data
No Data available this quarter, please select a different quarter.
53.82%
Below half of TRVN's -6.82%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
54.98%
Below half of TRVN's -6.01%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-8.67%
≥ 1.5x TRVN's -0.68%. David Dodd sees more aggressive capex. Confirm it's not overspending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.00%
≥ 1.5x TRVN's -0.50%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
53.46%
Below half of TRVN's -5.61%. Michael Burry sees a potential red flag for stagnation or capital shortage.
21.21%
Less than half of TRVN's -2.60%. David Dodd sees a more disciplined AP approach or lower volume.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-57.02%
50-75% of TRVN's -97.53%. Bruce Berkowitz notes a more controlled liability line.
37.02%
Less than half of TRVN's -15.29%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
37.02%
Less than half of TRVN's -15.14%. David Dodd sees far fewer liability expansions relative to competitor.
37.77%
Above 1.5x TRVN's 9.68%. Michael Burry suspects heavy new equity expansion or dilution.
-3.87%
≥ 1.5x TRVN's -2.52%. David Dodd sees higher yoy retained profits than competitor.
-5.55%
50-75% of TRVN's -9.52%. Bruce Berkowitz notes relatively lower AOCI expansions.
No Data
No Data available this quarter, please select a different quarter.
59.08%
≥ 1.5x TRVN's 4.86%. David Dodd sees stronger capital base growth than competitor.
53.46%
Below half TRVN's -5.61%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-53.82%
1.25-1.5x TRVN's -40.32%. Martin Whitman is wary of heavier net leverage vs. competitor.